胺碘酮在急性心肌梗死并发室性心律失常中的临床应用  

Clinical application of amiodarone in ventricular arrhythmia secondary to acute myocardial infarction

作　　者：朱春磊[1] 梁林宝[1] 李小芳[1] 李春颜[1] 

机构地区：[1]高州市人民医院心外ICU,525200

出　　处：《国际医药卫生导报》2013年第9期1249-1252,共4页International Medicine and Health Guidance News

摘　　要：目的探讨静脉应用胺碘酮在急性心肌梗死（AMI）并发室性心律失常中的疗效。方法随机将98例发生急性心肌梗死并发室性心律失常住院患者分成两组，两组患者均在积极治疗AMI的基础上抗心律失常治疗，治疗组胺碘酮组（48例）静脉应用胺碘酮，对照组（50例）静脉应用利多卡因。比较两组患者的临床疗效、不良反应。结果治疗组有效41例（85．4％），死亡4例（8．3％）。不良反应6例（12．5％）；对照组有效33例（66．0％），死亡13例（26．0％），不良反应15例（30．0％）。两组间比较差异有统计学意义（P〈0．05）。结论静脉应用胺碘酮是治疗急性心肌梗死并发室性心律失常的有效方法，疗效显著，不良反应少，临床应用安全。Objective To explore the efficacy of intravenous amiodarone for ventricular arrhythmia secondary to acute myocardial infarction （AMI）. Methods 98 hospitalized patients with acute myocardial infarction complicated by ventricular arrhythmia were randomly divided into a study group and a control group. Both groups received anti-arrbythmic treatment in addition to therapies for AMI. The strudy group （amiodarone group, 48 patients） received intravenous amiodarone; while the control group （lidocaine group, 50 paiients） received intravenous lidocaine. The clinical efficacy and adverse reactions were compared between the two groups. Results In the study group, the therapy was efficacious in 41 patients （85.4%）, 4 （8.3%） patients were dead, and 6 （12.5%） developed adverse reactions; in the control group, the therapy was efficacious in 33 （66.0%） patients, 13 （26.0%） were dead, and 15 （30.0%） developed adverse reactions, with a statistical difference between the two groups （P〈0.05）. Conclusions Intravenous amiodarone is effective and safe in the treatment of ventricular arrhythmia secondary to acute myocardial infarction, and it has fewer adverse reactions.

关 键 词：胺碘酮 利多卡因 急性心肌梗死 室性心律失常 

分 类 号：R541.7[医药卫生—心血管疾病]